KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.

Chengyuan Gu, Zengjun Wang, Tianxin Lin, Zhiyu Liu, Weiqing Han, Xuhui Zhang, Chao Liang, Hao Liu, Yang Yu, Zhenzhou Xu, Shuang Liu, Jingen Wang, Linghua Jia, Xin Yao, Wenfeng Liao, Cheng Fu, Zhaohui Tan, Guohua He, Guoxi Zhu, Rui Fan, Wenzeng Yang, Xin Chen, Zhizhong Liu, Liqiang Zhong, Benkang Shi, Degang Ding, Shubo Chen, Junli Wei, Xudong Yao, Ming Chen, Zhanpeng Lu, Qun Xie, Zhiquan Hu, Yinhuai Wang, Hongqian Guo, Tiwu Fan, Zhaozhao Liang, Peng Chen, Wei Wang, Tao Xu, Chunsheng Li, Jinchun Xing, Hong Liao, Dalin He, Zhibin Wu, Jiandi Yu, Zhongwen Feng, Mengxiang Yang, Qifeng Dou, Quan Zeng, Yuanwei Li, Xin Gou, Guangchen Zhou, Xiaofeng Wang, Rujian Zhu, Zhonghua Zhang, Bo Zhang, Wanlong Tan, Xueling Qu, Hongliang Sun, Tianyi Gan, Dingwei Ye

Chin Med J (Engl) 136(10) 1207-1215

PMID37010251
PMCIDPMC10278759
DOI10.1097/CM9.0000000000002638
发表日期2023-04-03
入排依据:The trial is a randomized Phase III oncology study with a drug intervention, but its primary efficacy endpoint is the percentage of patients achieving a pharmacodynamic endpoint (testosterone suppression ≤50 ng/dL) and its cumulative probability over a fixed time period (day 29 to 85). This is not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier curve or hazard ratio for such an endpoint is described.
摘要

摘要

BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels. RESULTS: On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]). CONCLUSION: LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04563936.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。